Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
Hematol Oncol
; 31(3): 151-5, 2013 Sep.
Article
en En
| MEDLINE
| ID: mdl-23108910
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Resistencia a Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Evaluation_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
Hematol Oncol
Año:
2013
Tipo del documento:
Article